

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone / Posaconazole / Gentamicin / Polymyxin B
Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product
stance/Mixture

Recommended restrictions : Not applicable
on use

1.3 Details of the supplier of the safety data sheet

Company : MSD
Drynam Road
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person : EHSDATASTEWARD@msd.com
responsible for the SDS

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A	H360D: May damage the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360D May damage the unborn child. H373 May cause damage to organs through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention: P201 Obtain special instructions before use. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. Response: P308 + P313 IF exposed or concerned: Get medical advice/ attention. P391 Collect spillage. Storage: P405 Store locked up.

Hazardous components which must be listed on the label:

Gentamicin

Additional Labelling

EUH208 Contains 3-Mercaptopropane-1,2-diol. May produce an allergic reaction.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 8.1 Revision Date: 14.04.2025 SDS Number: 778796-00025 Date of last issue: 03.12.2024
Date of first issue: 23.06.2016

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1	$\geq 1 - < 2.5$
Posaconazole	171228-49-2	Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Adrenal gland, Bone marrow, Kidney, Liv- er, Nervous system, Reproductive organs) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	$\geq 0.25 - < 1$
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100	$\geq 0.25 - < 0.3$
3-Mercaptopropane-1,2-diol	96-27-5 202-495-0	Acute Tox. 4; H302 Acute Tox. 3; H311 Skin Irrit. 2; H315 Eye Irrit. 2; H319 Skin Sens. 1B; H317	$\geq 0.1 - < 1$

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

		Acute toxicity estimate	
		Acute oral toxicity: 648 mg/kg	
		Acute dermal toxicity: 673 mg/kg	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | |
|-------|---|
| Risks | : May produce an allergic reaction.

May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure. |
|-------|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | |
|-----------|---|
| Treatment | : Treat symptomatically and supportively. |
|-----------|---|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types: |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 8.1 Revision Date: 14.04.2025 SDS Number: 778796-00025 Date of last issue: 03.12.2024
Date of first issue: 23.06.2016

Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Gentamicin	1403-66-3	TWA	0.1 mg/m ³ (OEB 2)	Internal
	Further information: OTO			
Posaconazole	171228-49-2	TWA	300 µg/m ³ (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
triacetin	Workers	Inhalation	Long-term systemic effects	35.275 mg/m ³
	Workers	Skin contact	Long-term systemic effects	5 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	8.7 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	2.5 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	2.5 mg/kg bw/day
3-Mercaptopropane-1,2-diol	Workers	Ingestion	Long-term systemic effects	0.49 mg/m ³
	Workers	Skin contact	Long-term systemic effects	0.14 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.074 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	0.05 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.05 mg/kg bw/day

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
triacetin	Fresh water	1.88 mg/l
	Marine water	0.188 mg/l
	Intermittent use/release	1 mg/l
	Sewage treatment plant	1088 mg/l
	Fresh water sediment	4.73 mg/kg
	Marine sediment	0.47 mg/kg
	Soil	0.57 mg/kg
3-Mercaptopropane-1,2-diol	Oral (Secondary Poisoning)	69.9 mg/kg food
	Fresh water	0.006 mg/l
	Freshwater - intermittent	0.057 mg/l
	Marine water	0.001 mg/l

8.2 Exposure controls

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

sure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter should conform to I.S. EN 14387
Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	: liquid
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
pH	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Vapour pressure	:	No data available
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	Can react with strong oxidizing agents.
---------------------	---	---

10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Acute toxicity

Not classified based on available information.

Product:

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg
LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous
LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular
LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

Posaconazole:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 3,000 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.
LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

administration)

Application Route: Subcutaneous
Symptoms: Breathing difficulties

3-Mercaptopropane-1,2-diol:

Acute oral toxicity : LD50 (Rat): 648 mg/kg

Acute dermal toxicity : LD50 (Rabbit): 673 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Gentamicin:

Species : Rabbit
Result : Mild skin irritation

Posaconazole:

Species : Rabbit
Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

3-Mercaptopropane-1,2-diol:

Species : Rabbit
Result : Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Gentamicin:

Species : Rabbit
Result : Mild eye irritation

Posaconazole:

Species : Rabbit
Result : Mild eye irritation

Mometasone:

Species : Rabbit
Result : No eye irritation

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

3-Mercaptopropane-1,2-diol:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Gentamicin:

Remarks : No data available

Posaconazole:

Test Type : Magnusson-Kligman-Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Mometasone:

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitisation.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

3-Mercaptopropane-1,2-diol:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation rate in humans

Germ cell mutagenicity

Not classified based on available information.

Components:

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

Posaconazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intravenous
Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

3-Mercaptopropane-1,2-diol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Gentamicin:

Carcinogenicity - Assessment : No data available

Posaconazole:

Species : Rat
Application Route : oral (feed)
Exposure time : 2 Years
Result : positive
Remarks : The mechanism or mode of action is not relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : positive
Remarks : The mechanism or mode of action is not relevant in humans.

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Dose : 0.067 mg/kg body weight

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Result : negative

Species : Mouse

Application Route : Inhalation

Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

Reproductive toxicity

May damage the unborn child.

Components:

Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Fertility: NOAEL: 20 mg/kg body weight
Result: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: NOAEL: 3.6 mg/kg body weight
Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 75 mg/kg body weight
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Mouse
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male
General Toxicity - Parent: NOAEL: 180 mg/kg body weight
Symptoms: No effects on mating performance
Result: negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

		Test Type: Fertility/early embryonic development Species: Rat, female General Toxicity - Parent: NOAEL: 45 mg/kg body weight Symptoms: No effects on mating performance Result: negative
Effects on foetal develop- ment	:	Test Type: Embryo-foetal development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity, Malformations were observed. Test Type: Embryo-foetal development Species: Rabbit, female Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity
Reproductive toxicity - As- sessment	:	Some evidence of adverse effects on development, based on animal experiments.
Mometasone:		
Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
Effects on foetal develop- ment	:	Test Type: Embryo-foetal development Species: Mouse Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen- tal toxicity Test Type: Embryo-foetal development Species: Rat Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight Result: Embryo-foetal toxicity Test Type: Embryo-foetal development Species: Rabbit Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed. Test Type: Embryo-foetal development Species: Rat

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
Result: Effects on newborn

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

3-Mercaptopropane-1,2-diol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Gentamicin:

Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

Posaconazole:

Exposure routes : Ingestion

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Target Organs : Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system

Assessment : Causes damage to organs through prolonged or repeated exposure.

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Gentamicin:

Species : Dog

LOAEL : 3 mg/kg

Application Route : Intramuscular

Exposure time : 12 Months

Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey

LOAEL : 50 mg/kg

Application Route : Subcutaneous

Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey

LOAEL : 6 mg/kg

Application Route : Intramuscular

Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12.5 mg/kg

LOAEL : 50 mg/kg

Application Route : Intramuscular

Exposure time : 13 Weeks

Target Organs : Kidney

Posaconazole:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Species	: Rat, female
LOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 392 Days
Target Organs	: Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species	: Monkey
LOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Bone marrow, Adrenal gland, Lymph nodes, Blood

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 56 Weeks
Target Organs	: Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species	: Monkey
LOAEL	: 180 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Blood, Gastrointestinal tract, spleen

Species	: Monkey
LOAEL	: 8 mg/kg
Application Route	: Intravenous
Exposure time	: 1 Months
Target Organs	: Cardio-vascular system, Lungs, Adrenal gland, Blood

Mometasone:

Species	: Rat
NOAEL	: 0.005 mg/kg
LOAEL	: 0.3 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Dog
LOAEL	: 0.5 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Species : Rat
NOAEL : 0.00013 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,
Kidney, Liver, thymus gland

Species : Dog
NOAEL : 0.0005 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 90 d
Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,
Kidney, thymus gland, Liver

3-Mercaptopropane-1,2-diol:

Species : Rat
LOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 55 Days
Method : OECD Test Guideline 422
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Gentamicin:

Ingestion : Target Organs: Kidney

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Posaconazole:

Ingestion

: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance

Mometasone:

Inhalation

: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact

: Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks

: Dermal absorption possible

SECTION 12: Ecological information

12.1 Toxicity

Components:

Gentamicin:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l
Exposure time: 72 h

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 100

Toxicity to microorganisms : EC50 : 288.7 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity) : 1

Posaconazole:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.276 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 0.206 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.244 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

M-Factor (Chronic aquatic toxicity) : 1

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC : 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0.00014 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.34 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

toxicity)

3-Mercaptopropane-1,2-diol:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 10 - 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 10 - 100 mg/l
aquatic invertebrates
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae/aquatic : ErC50 (Raphidocelis subcapitata (freshwater green alga)): >
plants
10 - 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

EC10 (Raphidocelis subcapitata (freshwater green alga)): > 1
mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (activated sludge): > 1 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:

Gentamicin:

Biodegradability : Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Posaconazole:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 h
Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d
Method: OECD Test Guideline 111

Mometasone:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)
Method: OECD Test Guideline 111

3-Mercaptopropane-1,2-diol:

Biodegradability : Result: Readily biodegradable.
Remarks: Based on data from similar materials

12.3 Bioaccumulative potential

Components:

Gentamicin:

Partition coefficient: n-octanol/water : log Pow: < -2

Posaconazole:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 20
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.15

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

3-Mercaptopropane-1,2-diol:

Partition coefficient: n-octanol/water : log Pow: -0.84
Method: OECD Test Guideline 117

12.4 Mobility in soil

Components:

Posaconazole:

Distribution among environmental compartments : log Koc: 5.52

Mometasone:

Distribution among environmental compartments : log Koc: 4.02

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: UN 3082
ADR	: UN 3082
RID	: UN 3082
IMDG	: UN 3082
IATA	: UN 3082

14.2 UN proper shipping name

ADN	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
-----	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Gentamicin, Mometasone)
IATA	:	Environmentally hazardous substance, liquid, n.o.s. (Gentamicin, Mometasone)

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN	
Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
ADR	
Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
Tunnel restriction code	: (-)
RID	
Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
IMDG	
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
IATA (Cargo)	
Packing instruction (cargo)	: 964

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

aircraft)
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E1	ENVIRONMENTAL HAZARDS	Quantity 1 100 t	Quantity 2 200 t
----	--------------------------	---------------------	---------------------

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H311 : Toxic in contact with skin.

H315 : Causes skin irritation.

H317 : May cause an allergic skin reaction.

H319 : Causes serious eye irritation.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

H360D	:	May damage the unborn child.
H360Df	:	May damage the unborn child. Suspected of damaging fertility.
H361d	:	Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.
H373	:	May cause damage to organs through prolonged or repeated exposure if inhaled.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Aquatic Acute	:	Short-term (acute) aquatic hazard
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
Skin Irrit.	:	Skin irritation
Skin Sens.	:	Skin sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 03.12.2024
8.1	14.04.2025	778796-00025	Date of first issue: 23.06.2016

- Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 1A	H360D
STOT RE 2	H373
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN